Aldevron News / James Brown

Aldevron, Sanford Health, North Dakota State University highlight advances in rare disease treatment

Area organizations Aldevron, Sanford Health, and North Dakota State University (NDSU) have joined forces to bring together a special event titled, "From the Valley to the Mountain: The RARE Impact of the Red River Valley," on Wednesday, April 11 from 5:30-8 p.m. at Aldevron corporate headquarters, 4837 Amber Valley Parkway, Fargo N.D. The evening will start with refreshments, a Meet and Greet, and a silent auction, followed by leaders in science and medicine from the Red River Valley sharing their contributions toward advancing gene therapy and rare disease research efforts around the world.

Read More

Aldevron announces ready-to-use helper plasmid for AAV manufacturing

New plasmid to reduce cost and timeline for gene therapy manufacturing

Aldevron, the world’s leading contract plasmid manufacturing organization, has announced the immediate availability of an off-the-shelf version of pXX6-80, a common adeno-associated virus (AAV) helper plasmid. The plasmid is designed to reduce the cost of AAV manufacturing and subsequent gene therapy applications, while helping Aldevron’s clients meet regulatory requirements.

Read More

Aldevron and the University of Minnesota collaborate in supporting Rare Disease Day

Aldevron is a sponsor for the Rare Disease Day program, "Gene Therapy for Rare Diseases: Promise and Challenges", presented by the University of Minnesota Center for Orphan Drug Research and Stem Cell Institute on February 23, 2018. Dr. Jakub Tolar, Dean, Medical School, University of Minnesota, will moderate the event, which will include presentations by University of Minnesota faculty and a representative from Abeona Therapeutics.

Read More

Aldevron Announces Growth Investment from TA Associates

(Fargo, N.D. and Boston, Mass.), January 24, 2017 – Aldevron, a contract development and manufacturing organization specializing in the production of plasmid DNA, proteins and antibodies, today announced it has received a growth investment from TA Associates, a leading global growth private equity firm. Aldevron’s management retains a significant portion of ownership in the company and will continue to run the company. Financial terms of the transaction were not disclosed.

Founded in 1998, Aldevron manufactures biologics for research, clinical and diagnostic applications. The company’s products are used to manufacture novel treatments for a wide range of indications, including cancer, infectious disease, pediatric disorders and rare diseases. Aldevron’s custom products are used extensively in the fields of gene therapy and gene editing. The company is headquartered in Fargo, North Dakota, and has additional facilities in Madison, Wisconsin, and Freiburg, Germany.

Read More

Aldevron Participates in Panel Discussion at Rejuvenation Biotechnology 2016

Dr. James Brown, Aldevron’s Vice President of Corporate Development, will be speaking on a panel at the Rejuvenation Biotechnology 2016 Conference at the Buck Institute for Research on Aging in Novato, California.

The conference takes place August 16-17 and the panel titled “As Paths To Clinic Are Expedited, The Distinction Between Development And Manufacturing Is Becoming Increasingly Blurred” will be on August 17 from 10:15 AM to Noon PST.

Dr. Brown will be joined by fellow panelists Sean Kevlahan, Chief Executive Officer and Co-founder of Quad Technologies, and Alan Moore, Vice President and Commercial Chief for Biologics and Advanced Therapies of Wuxi AppTec. The panel will be moderated by Eric Roos, Strategic Alliances Leader, Cell Therapy, Thermo Fisher Scientific.

Read More